Diagnostics: Page
-
Illumina names former NIH genomics director as chief medical officer
The company unveiled the appointment alongside news of the departure of its chief commercial officer.
By Nick Paul Taylor • Jan. 12, 2026 -
Philips to acquire SpectraWAVE
SpectraWAVE makes technologies to help diagnose and guide treatment decisions for coronary artery disease.
By Elise Reuter • Dec. 15, 2025 -
Explore the Trendline➔
Sarah Silbiger via Getty Images
TrendlineTop 5 stories from MedTech Dive
From the effects of layoffs at the Food and Drug Administration and President Donald Trump’s tariff policies to the top medtech trends of 2026, here is a collection of top stories from MedTech Dive.
By MedTech Dive staff -
Natera acquires Foresight Diagnostics for up to $450M
Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in 2026.
By Susan Kelly • Dec. 10, 2025 -
GE HealthCare, Mayo Clinic expand partnership around radiology research
Ben Newton, GE HealthCare’s global head of oncology, said the partnership will shift radiation therapy from a “one-size-fits-all” approach to a personalized method.
By Elise Reuter • Dec. 9, 2025 -
Freenome inks deals to list stock and raise $330M
The company plans to use the proceeds to expand its commercial and data infrastructure to support the launch of multiple blood-based cancer detection tests.
By Nick Paul Taylor • Dec. 8, 2025 -
CHS sells lab assets to Labcorp for $194M
The deal, first announced in July, includes outreach laboratory services in 13 states. CHS will continue to operate inpatient and emergency department labs.
By Susanna Vogel • Dec. 4, 2025 -
PitchBook: AI tuck-in deals to drive M&A acceleration in 2026
Buyers will focus on “tuck-ins that add AI or data-driven capabilities or can meaningfully improve scale against emerging competitors,” the analysts said.
By Nick Paul Taylor • Dec. 3, 2025 -
Cleveland Diagnostics wins FDA nod for prostate cancer test
The IsoPSA test is intended to help assess whether patients with elevated PSA levels should go on to receive a biopsy procedure.
By Susan Kelly • Dec. 2, 2025 -
Abbott’s $21B Exact Sciences buy reveals future strategy
The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer testing.
By Elise Reuter • Nov. 21, 2025 -
Roche inks deal for rights to Freenome cancer tests outside US
Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits, similar to with their prior success in IVD kits.”
By Nick Paul Taylor • Nov. 20, 2025 -
Abbott to acquire Exact Sciences for about $21B
The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early detection.
By Elise Reuter , Susan Kelly • Updated Nov. 20, 2025 -
Labcorp inks deal to buy Parkview Health outreach laboratory assets
The takeover extends a string of deals that have consolidated the outreach lab services market.
By Nick Paul Taylor • Nov. 14, 2025 -
Siemens to reduce stake in Siemens Healthineers
Siemens Healthineers CEO Bernd Montag said the decision is a “natural next step in our journey to becoming a fully independent company.”
By Susan Kelly • Nov. 13, 2025 -
Retrieved from Olympus on February 03, 2025
Olympus to cut 2,000 jobs in endoscopy reorganization
The workforce reduction is part of a restructuring designed to improve accountability and accelerate growth and innovation.
By Susan Kelly • Nov. 7, 2025 -
Health groups urge passage of bill to ease Medicare pay cuts for tests
More than 30 organizations, including AdvaMed and the American Clinical Laboratory Association, are pushing for a permanent legislative solution to stop looming Medicare payment cuts for diagnostic tests.
By Susan Kelly • Nov. 3, 2025 -
Sponsored by Danaher
Turning aspirational innovations into tangible impacts
Making tomorrow’s breakthroughs a reality for the patients who need.
Nov. 3, 2025 -
Agilent selects Adam Elinoff as CFO
The appointment fills a position made available when Bob McMahon resigned as CFO on July 31.
By Nick Paul Taylor • Oct. 31, 2025 -
Profile
Hemorrhage can be a serious problem after pregnancy. Here’s how one medtech founder is tackling it
Kelsey Mayo, CEO of Armor Medical, received the grand prize in MedTech Innovator’s pitch competition for a wearable technology to detect serious blood loss early.
By Elise Reuter • Oct. 23, 2025 -
Hologic to go private for up to $18.3B
Funds managed by Blackstone and TPG plan to acquire the medtech firm for up to $79 per share.
By Elise Reuter • Oct. 21, 2025 -
AdvaMed calls for series of trade actions in response to Section 232 probe
In comments submitted to the Trump administration on its medical equipment investigation, the industry group recommended a tariff-free trading bloc with trusted countries among its proposals.
By Susan Kelly • Oct. 20, 2025 -
BD CFO Chris DelOrefice leaving for new job
Along with DelOrefice’s departure, BD reported preliminary fiscal fourth-quarter revenue that analysts said was below Wall Street consensus expectations.
By Susan Kelly • Oct. 16, 2025 -
Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout
The Sanofi partnership will support clinical validation and regulatory submissions for Revvity’s new assay. Elsewhere, Kihealth raised $5 million in seed funding to launch its early detection test.
By Susan Kelly • Oct. 6, 2025 -
CDRH shares regulatory guidance priorities for the coming 12 months
Use of real-world evidence to support regulatory decisions and predetermined change control plans for medical devices are two areas of focus for the agency.
By Nick Paul Taylor • Oct. 2, 2025 -
MedTech Europe pressures EU to make regulatory changes by early 2026
The request includes a call to postpone re-certification requirements for devices already certified under the medical technology regulations.
By Nick Paul Taylor • Sept. 26, 2025 -
Quest to distribute Guardant colon cancer blood test
Guardant Health Co-CEO AmirAli Talasaz also unveiled plans to launch the Shield test for multi-cancer detection in October.
By Susan Kelly • Sept. 25, 2025